GlaxoSmithKline has further slowed its share buy-back programme in recent weeks as it builds up cash reserves for potential deals in spite of the drying up of external credit.
The move marks one of a range of actions taken by large pharmaceutical companies to adapt to the current market difficulties, while benefiting from a cash-rich position that protects most of them from the worst effects of the crisis.
